EcoDrugPlus

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSEEEG00000013247
Gene Symbol: FYNA
4 Cross references
192 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSEEEG00000013145
Gene Symbol: FYNB
4 Cross references
201 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSEEEG00000018014
Gene Symbol: GPR119
2 Cross references
176 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSEEEG00000007150
Gene Symbol: HCK
4 Cross references
203 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSEEEG00000010679
Gene Symbol: ITK
4 Cross references
208 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1a

Ensembl ID : ENSEEEG00000010302
Gene Symbol: IMPDH1A
2 Cross references
259 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSEEEG00000008957
Gene Symbol: IMPDH1B
4 Cross references
258 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSEEEG00000021122
Gene Symbol: IMPDH2
4 Cross references
202 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSEEEG00000006170
Gene Symbol: JAK1
2 Cross references
213 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSEEEG00000010462
Gene Symbol: JAK1
4 Cross references
167 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSEEEG00000013635
Gene Symbol: JAK2A
4 Cross references
198 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSEEEG00000022075
Gene Symbol: JAK2B
4 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).